Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues-Reference-Cited by-同舟云学术

Pneumocystis Pneumonia in Rheumatic Diseases: Prevention Issues

Published:2022-12-29 Issue:9-10 Volume:67 Page:79-89
ISSN:0235-2990
Container-title:Antibiotics and Chemotherapy
language:
Short-container-title:A&Ch

Author:

Gridneva G. I.¹^ORCID,Belov B. S.¹^ORCID,Aronova E. S.¹^ORCID

Affiliation:

1. V. A. Nasonova Research Injstitute of Rheumatology

Abstract

The incidence of pneumocystis pneumonia (PCP) in patients with rheumatic diseases (RD) continues to increase. This is facilitated by the increasing use of genetically engineered biological agents in addition to the use of cytostatics and glucocorticoids. Mortality due to PCP among patients with RD is extremely high, so the issues of its prevention are relevant. European and American scientists focus on the frequency of detection of PCP and the determination of the proportionality of certain risk factors, while the recommendations for prevention are formulated cautiously. Asian medical communities are unanimous in their opinion about the need to prevent PCP, only the dosage of drugs and the duration of the course of treatment are discussed.

Publisher

Publishing House OKI

Subject

Infectious Diseases,Microbiology (medical),General Medicine,Microbiology

Reference61 articles.

1. Karazhas N.V., Rybalkina T.N., Kornienko M.N., Yuditskii M.V. Pnevmotsistoz — aktual'naya immunodefitsit-assotsiirovannaya infektsiya: Metodicheskie rekomendatsii. M.: 2009; 75. [Karazhas N.V., Rybalkina T.N., Kornienko M.N., Jyuditskij M.V. Pnevmotsistoz — aktual'naya immunodefitsit-assotsiirovannaya infektsiya: Metodicheskie reko-mendatsii. Moscow: 2009; 75. (in Russian)]

2. Furukawa H., Oka S., Shimada K. et al. Serum metabolomic profiles of rheumatoid arthritis patients with acute-onset diffuse interstitial lung disease. Biomark Insights. 2019 Aug 22; 14: 1177271919870472. doi: 10.1177/1177271919870472. eCollection 2019.

3. Kovacs J.A., Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA. 2009 Jun 24; 301 (24): 2578–2585. doi: 10.1001/jama.2009.880.

4. Menon A.A., Berg D.D., Brea E.J. et al. A sase of COVID-19 and zneumocystis jirovecii coinfection. Am J Respir Crit Care Med. 2020 Jul 1; 202 (1): 136–138. doi: 10.1164/rccm.202003-0766LE.

5. Belov B.S., Tarasova G.M., Bukhanova D.S. Profilaktika pnevmotsistnoi pnevmonii u patsientov s revmaticheskimi zabolevaniyami: problemy i poisk reshenii. Antibiotiki i khimioter. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035. [Belov B. S., Tarasova G. M., Bukhanova D. S. Prevention of pneumocystic pneumonia in patients with rheumatic diseases: problems and solutions. Antibiotiki i Khimioter = Antibiotics and Chemotherapy. 2019; 64 (5–6): 77–89. https://doi.org/10.24411/0235-2990-2019-10035.